Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs

S. P. Sivam, J. E. Krause, K. Takeuchi, S. Li, J. F. McGinty, J. S. Hong

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Previous reports indicate that the antimanic drug, lithium, increases substance P-like immunoreactivity (SP-LI) in the basal ganglia. The aim of this study was to use lithium as a pharmacological tool to further understand the mechanism of this process. We have used solution hybridization-nuclease protection assays to quantitate the specific preprotachykinin (PPT) mRNAs and radioimmunoassays and immunocytochemistry to assess SP-LI levels in the striatum of male Fisher F-344 rats. A regimen of subchronic administration of lithium (4 mEq/kg i.p. for 1, 2, 4 or 6 days) increased SP-LI in a time-dependent fashion. Concurrent administration of a dopamine receptor antagonist, haloperidol (1 mg/kg s.c. for 4 days) with a 4-day lithium regimen partially blocked the lithium-induced increase in SP-LI as well as neurokinin A-like immunoreactivity. An analysis of the abundance of individual PPT mRNAs indicated that lithium increases beta- and gamma-PPT mRNAs in the striatum; coadministration of haloperidol attenuates the lithium-induced increases. These results indicate that lithium affects the tachykinin biosynthetic process by accelerating transcriptional and/or translational processes in striatonigral neurons and that the dopaminergic system appears to be partly involved in this process.

Original languageEnglish (US)
Pages (from-to)1297-1301
Number of pages5
JournalJournal of Pharmacology and Experimental Therapeutics
Volume248
Issue number3
StatePublished - Jan 1 1989

Fingerprint

Corpus Striatum
Lithium
Messenger RNA
Substance P
Haloperidol
Nuclease Protection Assays
Antimanic Agents
Neurokinin A
Tachykinins
Dopamine Antagonists
preprotachykinin
Dopaminergic Neurons
Basal Ganglia
Radioimmunoassay
Immunohistochemistry
Pharmacology

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Sivam, S. P., Krause, J. E., Takeuchi, K., Li, S., McGinty, J. F., & Hong, J. S. (1989). Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs. Journal of Pharmacology and Experimental Therapeutics, 248(3), 1297-1301.

Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs. / Sivam, S. P.; Krause, J. E.; Takeuchi, K.; Li, S.; McGinty, J. F.; Hong, J. S.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 248, No. 3, 01.01.1989, p. 1297-1301.

Research output: Contribution to journalArticle

Sivam, SP, Krause, JE, Takeuchi, K, Li, S, McGinty, JF & Hong, JS 1989, 'Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs', Journal of Pharmacology and Experimental Therapeutics, vol. 248, no. 3, pp. 1297-1301.
Sivam, S. P. ; Krause, J. E. ; Takeuchi, K. ; Li, S. ; McGinty, J. F. ; Hong, J. S. / Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs. In: Journal of Pharmacology and Experimental Therapeutics. 1989 ; Vol. 248, No. 3. pp. 1297-1301.
@article{fe76c916e6244ba299eb60b6333af258,
title = "Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs",
abstract = "Previous reports indicate that the antimanic drug, lithium, increases substance P-like immunoreactivity (SP-LI) in the basal ganglia. The aim of this study was to use lithium as a pharmacological tool to further understand the mechanism of this process. We have used solution hybridization-nuclease protection assays to quantitate the specific preprotachykinin (PPT) mRNAs and radioimmunoassays and immunocytochemistry to assess SP-LI levels in the striatum of male Fisher F-344 rats. A regimen of subchronic administration of lithium (4 mEq/kg i.p. for 1, 2, 4 or 6 days) increased SP-LI in a time-dependent fashion. Concurrent administration of a dopamine receptor antagonist, haloperidol (1 mg/kg s.c. for 4 days) with a 4-day lithium regimen partially blocked the lithium-induced increase in SP-LI as well as neurokinin A-like immunoreactivity. An analysis of the abundance of individual PPT mRNAs indicated that lithium increases beta- and gamma-PPT mRNAs in the striatum; coadministration of haloperidol attenuates the lithium-induced increases. These results indicate that lithium affects the tachykinin biosynthetic process by accelerating transcriptional and/or translational processes in striatonigral neurons and that the dopaminergic system appears to be partly involved in this process.",
author = "Sivam, {S. P.} and Krause, {J. E.} and K. Takeuchi and S. Li and McGinty, {J. F.} and Hong, {J. S.}",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "248",
pages = "1297--1301",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs

AU - Sivam, S. P.

AU - Krause, J. E.

AU - Takeuchi, K.

AU - Li, S.

AU - McGinty, J. F.

AU - Hong, J. S.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Previous reports indicate that the antimanic drug, lithium, increases substance P-like immunoreactivity (SP-LI) in the basal ganglia. The aim of this study was to use lithium as a pharmacological tool to further understand the mechanism of this process. We have used solution hybridization-nuclease protection assays to quantitate the specific preprotachykinin (PPT) mRNAs and radioimmunoassays and immunocytochemistry to assess SP-LI levels in the striatum of male Fisher F-344 rats. A regimen of subchronic administration of lithium (4 mEq/kg i.p. for 1, 2, 4 or 6 days) increased SP-LI in a time-dependent fashion. Concurrent administration of a dopamine receptor antagonist, haloperidol (1 mg/kg s.c. for 4 days) with a 4-day lithium regimen partially blocked the lithium-induced increase in SP-LI as well as neurokinin A-like immunoreactivity. An analysis of the abundance of individual PPT mRNAs indicated that lithium increases beta- and gamma-PPT mRNAs in the striatum; coadministration of haloperidol attenuates the lithium-induced increases. These results indicate that lithium affects the tachykinin biosynthetic process by accelerating transcriptional and/or translational processes in striatonigral neurons and that the dopaminergic system appears to be partly involved in this process.

AB - Previous reports indicate that the antimanic drug, lithium, increases substance P-like immunoreactivity (SP-LI) in the basal ganglia. The aim of this study was to use lithium as a pharmacological tool to further understand the mechanism of this process. We have used solution hybridization-nuclease protection assays to quantitate the specific preprotachykinin (PPT) mRNAs and radioimmunoassays and immunocytochemistry to assess SP-LI levels in the striatum of male Fisher F-344 rats. A regimen of subchronic administration of lithium (4 mEq/kg i.p. for 1, 2, 4 or 6 days) increased SP-LI in a time-dependent fashion. Concurrent administration of a dopamine receptor antagonist, haloperidol (1 mg/kg s.c. for 4 days) with a 4-day lithium regimen partially blocked the lithium-induced increase in SP-LI as well as neurokinin A-like immunoreactivity. An analysis of the abundance of individual PPT mRNAs indicated that lithium increases beta- and gamma-PPT mRNAs in the striatum; coadministration of haloperidol attenuates the lithium-induced increases. These results indicate that lithium affects the tachykinin biosynthetic process by accelerating transcriptional and/or translational processes in striatonigral neurons and that the dopaminergic system appears to be partly involved in this process.

UR - http://www.scopus.com/inward/record.url?scp=0024601661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024601661&partnerID=8YFLogxK

M3 - Article

C2 - 2467980

AN - SCOPUS:0024601661

VL - 248

SP - 1297

EP - 1301

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -